Prostate Cancer Treatment Pluvicto Currently in Shortage
Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
The approval was based on data from the phase 3 ARASENS trial.
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
The authors of a new review discuss priorities, adjustments, and tailored approaches to prostate cancer management during the COVID-19 pandemic.
Disparities in access to medical care are among the factors thought to contribute to geographic variations in prostate cancer death rates and the treatments patients receive.
The World Health Organization (WHO) has updated the WHO Model List of Essential Medicines for 2019.